{"id":5642,"date":"2023-12-01T12:02:25","date_gmt":"2023-12-01T17:02:25","guid":{"rendered":"https:\/\/neoaptamers.com\/?p=5642"},"modified":"2026-04-08T14:30:58","modified_gmt":"2026-04-08T18:30:58","slug":"aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria","status":"publish","type":"post","link":"https:\/\/neoaptamers.com\/es\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/","title":{"rendered":"Caso de Uso de Aptamarcadores: Mejorando los Ensayos Cl\u00ednicos con Precisi\u00f3n de Aptamarcadores - Adaptando los Criterios de Inclusi\u00f3n y Exclusi\u00f3n"},"content":{"rendered":"<ul>\n<li>La plataforma de Aptamarkers de NeoVentures Biotechnology revoluciona los ensayos cl\u00ednicos al introducir criterios de inclusi\u00f3n y exclusi\u00f3n personalizados y predictivos.<\/li>\n<li>Los Aptamarkers se entrenan utilizando muestras biol\u00f3gicas y las respuestas al tratamiento de los participantes, lo que permite una prueba de qPCR rentable para el cribado de individuos que ingresan a ensayos cl\u00ednicos.<\/li>\n<li>Las capacidades predictivas de los Aptamarkers permiten a los investigadores adaptar los criterios de inclusi\u00f3n para respuestas positivas al tratamiento y los criterios de exclusi\u00f3n para aquellos propensos a efectos secundarios, mejorando las tasas de \u00e9xito del ensayo, la seguridad de los participantes y la eficiencia general en el desarrollo de medicamentos.<\/li>\n<\/ul>\n<p>Los ensayos cl\u00ednicos son etapas clave en el desarrollo de medicamentos, proporcionando informaci\u00f3n invaluable sobre la eficacia y seguridad de un tratamiento. El enfoque tradicional para el dise\u00f1o de ensayos cl\u00ednicos implica definir criterios de inclusi\u00f3n y exclusi\u00f3n estrictos basados en caracter\u00edsticas de la poblaci\u00f3n general. Sin embargo, la naturaleza din\u00e1mica de las respuestas individuales a los tratamientos requiere una estrategia m\u00e1s personalizada y predictiva. La plataforma de Aptamarkers de NeoVentures Biotechnology est\u00e1 revolucionando el panorama de los ensayos cl\u00ednicos al ofrecer una soluci\u00f3n sofisticada para adaptar los criterios de inclusi\u00f3n y exclusi\u00f3n con una precisi\u00f3n sin precedentes.<\/p>\n<h2>La Din\u00e1mica de los Ensayos Cl\u00ednicos<\/h2>\n<p>El coraz\u00f3n de los ensayos cl\u00ednicos radica en la generaci\u00f3n de nueva informaci\u00f3n, pero el viaje est\u00e1 lejos de ser uniforme para cada participante. Algunas personas pueden experimentar efectos secundarios inesperados, mientras que otras pueden responder excepcionalmente bien al tratamiento. Reconociendo esta variabilidad, Aptamarker introduce un cambio de paradigma al permitir el entrenamiento de aptamarcadores para predecir los resultados individuales de los ensayos cl\u00ednicos.<\/p>\n<h2>Entrenamiento de Aptamarkers para Predicciones Personalizadas<\/h2>\n<p>El proceso comienza aplicando la biblioteca de Aptamarkers a muestras biol\u00f3gicas obtenidas de individuos que ingresan a un ensayo cl\u00ednico. Esta aplicaci\u00f3n previa al tratamiento proporciona una comprensi\u00f3n inicial del panorama biomolecular de los participantes. Simult\u00e1neamente, la plataforma requiere conocimiento de las reacciones de estos individuos al tratamiento durante el ensayo. Este enfoque de doble entrada es esencial para entrenar a los Aptamarkers para reconocer biomarcadores espec\u00edficos asociados con la respuesta al tratamiento o reacciones adversas.<\/p>\n<h2>Detecci\u00f3n Rentable a trav\u00e9s de Pruebas de qPCR<\/h2>\n<p>Una vez que los Aptamarkers est\u00e1n entrenados, su traducci\u00f3n a una simple prueba cuantitativa de reacci\u00f3n en cadena de la polimerasa (qPCR) se convierte en un cambio de juego. Esta transformaci\u00f3n permite un proceso de cribado rentable y eficiente para los individuos que ingresan a ensayos cl\u00ednicos. La prueba de qPCR, basada en la biblioteca de Aptamarkers, act\u00faa como una herramienta diagn\u00f3stica, proporcionando informaci\u00f3n r\u00e1pida sobre la probabilidad de que un individuo responda favorablemente al tratamiento o experimente efectos secundarios no deseados.<\/p>\n<h2>Adaptaci\u00f3n de Criterios de Inclusi\u00f3n y Exclusi\u00f3n<\/h2>\n<p><em>Criterios de Inclusi\u00f3n:<\/em><\/p>\n<p>Las capacidades predictivas de los Aptamarkers permiten a los investigadores identificar individuos con predisposici\u00f3n a respuestas positivas al tratamiento. Al cribar a los posibles participantes seg\u00fan la prueba de qPCR de Aptamarker, los ensayos cl\u00ednicos pueden dise\u00f1arse para incluir a personas que tienen m\u00e1s probabilidades de beneficiarse del tratamiento, mejorando la tasa de \u00e9xito general del ensayo y optimizando la utilizaci\u00f3n de recursos.<\/p>\n<p><em>Criterios de Exclusi\u00f3n:<\/em><\/p>\n<p>Por el contrario, el cribado con Aptamarkers puede identificar individuos propensos a efectos secundarios no deseados o falta de respuesta. Este enfoque excluyente prioriza la seguridad de los participantes y simplifica el proceso del ensayo cl\u00ednico al eliminar candidatos menos propensos a obtener beneficios del tratamiento. Esto no solo mejora el perfil de seguridad general del ensayo, sino que tambi\u00e9n contribuye a una tuber\u00eda de desarrollo de medicamentos m\u00e1s eficiente y rentable.<\/p>\n<h2>Reposicionamiento de los Ensayos Cl\u00ednicos para Diferentes Indicaciones<\/h2>\n<p>La flexibilidad de los Aptamarkers se extiende m\u00e1s all\u00e1 del dise\u00f1o inicial del ensayo. Los conocimientos obtenidos del perfilado biomolecular de los participantes pueden facilitar el reposicionamiento de los ensayos cl\u00ednicos para diferentes indicaciones. Al comprender las respuestas \u00fanicas dentro de una poblaci\u00f3n, los investigadores pueden explorar aplicaciones terap\u00e9uticas alternativas sin empezar desde cero, potencialmente acelerando el desarrollo de tratamientos para diversas condiciones.<\/p>\n<p>En conclusi\u00f3n, la plataforma de Aptamarkers de NeoVentures Biotechnology est\u00e1 remodelando el futuro de los ensayos cl\u00ednicos. Al introducir una dimensi\u00f3n personalizada y predictiva a los criterios de inclusi\u00f3n y exclusi\u00f3n, los Aptamarkers aportan un nivel de precisi\u00f3n que antes era inimaginable. Este enfoque no solo mejora la eficiencia y las tasas de \u00e9xito de los ensayos cl\u00ednicos, sino que tambi\u00e9n garantiza un proceso de desarrollo de medicamentos m\u00e1s seguro y rentable. Al abrazar la era de los Aptamarkers, nos embarcamos en un viaje hacia un nuevo est\u00e1ndar de medicina personalizada e intervenciones terap\u00e9uticas dirigidas, avanzando finalmente en los l\u00edmites de la innovaci\u00f3n en salud.<\/p>","protected":false},"excerpt":{"rendered":"<p>NeoVentures Biotechnology&#8217;s Aptamarker platform revolutionizes clinical trials by introducing personalized and predictive inclusion and exclusion criteria. Aptamarkers are trained using biological samples and participants&#8217; treatment responses, enabling a cost-effective qPCR test for screening individuals entering clinical trials. The predictive capabilities of Aptamarkers allow researchers to tailor inclusion criteria for positive treatment responses and exclusion criteria&hellip;&nbsp;<a href=\"https:\/\/neoaptamers.com\/es\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/\" rel=\"bookmark\">Leer m\u00e1s &raquo;<span class=\"screen-reader-text\">Caso de Uso de Aptamarcadores: Mejorando los Ensayos Cl\u00ednicos con Precisi\u00f3n de Aptamarcadores - Adaptando los Criterios de Inclusi\u00f3n y Exclusi\u00f3n<\/span><\/a><\/p>","protected":false},"author":2,"featured_media":5644,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":70,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[8,39,1],"tags":[],"class_list":["post-5642","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aptamers","category-case-studies","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aptamarker Use Case: Enhancing Clinical Trials with Aptamarker Precision \u2013 Tailoring Inclusion and Exclusion Criteria<\/title>\n<meta name=\"description\" content=\"Explore NeoVentures&#039; Aptamarker platform, enhancing clinical trials with personalized, predictive criteria for safety and efficiency.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neoaptamers.com\/es\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptamarker Use Case: Enhancing Clinical Trials with Aptamarker Precision \u2013 Tailoring Inclusion and Exclusion Criteria\" \/>\n<meta property=\"og:description\" content=\"Explore NeoVentures&#039; Aptamarker platform, enhancing clinical trials with personalized, predictive criteria for safety and efficiency.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neoaptamers.com\/es\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/\" \/>\n<meta property=\"og:site_name\" content=\"neoaptamers\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-01T17:02:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-08T18:30:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/11\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1456\" \/>\n\t<meta property=\"og:image:height\" content=\"816\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Gregory Penner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gregory Penner\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/\"},\"author\":{\"name\":\"Gregory Penner\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/641d6a3e016e13414b8d0d0ffd5847ad\"},\"headline\":\"Aptamarker Use Case: Enhancing Clinical Trials with Aptamarker Precision \u2013 Tailoring Inclusion and Exclusion Criteria\",\"datePublished\":\"2023-12-01T17:02:25+00:00\",\"dateModified\":\"2026-04-08T18:30:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/\"},\"wordCount\":645,\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp\",\"articleSection\":[\"Aptamers\",\"Case Studies\",\"Uncategorized\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/\",\"name\":\"Aptamarker Use Case: Enhancing Clinical Trials with Aptamarker Precision \u2013 Tailoring Inclusion and Exclusion Criteria\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp\",\"datePublished\":\"2023-12-01T17:02:25+00:00\",\"dateModified\":\"2026-04-08T18:30:58+00:00\",\"description\":\"Explore NeoVentures' Aptamarker platform, enhancing clinical trials with personalized, predictive criteria for safety and efficiency.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/#primaryimage\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp\",\"width\":1456,\"height\":816,\"caption\":\"image of an aptamer under a microscope\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neoaptamers.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aptamarker Use Case: Enhancing Clinical Trials with Aptamarker Precision \u2013 Tailoring Inclusion and Exclusion Criteria\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"name\":\"Neoaptamers.com\",\"description\":\"Neoventures Biotechnology Inc.\",\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/neoaptamers.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\",\"name\":\"NeoVentures Biotechnology Inc.\",\"alternateName\":\"NVB\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"width\":500,\"height\":500,\"caption\":\"NeoVentures Biotechnology Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/neoventures-biotechnology-inc-\\\/\",\"https:\\\/\\\/www.reddit.com\\\/user\\\/NeoVenturesBiotech\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@neoaptamers7964\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/641d6a3e016e13414b8d0d0ffd5847ad\",\"name\":\"Gregory Penner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"caption\":\"Gregory Penner\"},\"description\":\"Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. \u00a0He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team.\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Caso de Uso de Aptamarcadores: Mejorando los Ensayos Cl\u00ednicos con Precisi\u00f3n de Aptamarcadores - Adaptando los Criterios de Inclusi\u00f3n y Exclusi\u00f3n","description":"Explore NeoVentures' Aptamarker platform, enhancing clinical trials with personalized, predictive criteria for safety and efficiency.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neoaptamers.com\/es\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/","og_locale":"es_ES","og_type":"article","og_title":"Aptamarker Use Case: Enhancing Clinical Trials with Aptamarker Precision \u2013 Tailoring Inclusion and Exclusion Criteria","og_description":"Explore NeoVentures' Aptamarker platform, enhancing clinical trials with personalized, predictive criteria for safety and efficiency.","og_url":"https:\/\/neoaptamers.com\/es\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/","og_site_name":"neoaptamers","article_published_time":"2023-12-01T17:02:25+00:00","article_modified_time":"2026-04-08T18:30:58+00:00","og_image":[{"width":1456,"height":816,"url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/11\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp","type":"image\/webp"}],"author":"Gregory Penner","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Gregory Penner","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/#article","isPartOf":{"@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/"},"author":{"name":"Gregory Penner","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/641d6a3e016e13414b8d0d0ffd5847ad"},"headline":"Aptamarker Use Case: Enhancing Clinical Trials with Aptamarker Precision \u2013 Tailoring Inclusion and Exclusion Criteria","datePublished":"2023-12-01T17:02:25+00:00","dateModified":"2026-04-08T18:30:58+00:00","mainEntityOfPage":{"@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/"},"wordCount":645,"publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"image":{"@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/11\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp","articleSection":["Aptamers","Case Studies","Uncategorized"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/","url":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/","name":"Caso de Uso de Aptamarcadores: Mejorando los Ensayos Cl\u00ednicos con Precisi\u00f3n de Aptamarcadores - Adaptando los Criterios de Inclusi\u00f3n y Exclusi\u00f3n","isPartOf":{"@id":"https:\/\/neoaptamers.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/#primaryimage"},"image":{"@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/11\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp","datePublished":"2023-12-01T17:02:25+00:00","dateModified":"2026-04-08T18:30:58+00:00","description":"Explore NeoVentures' Aptamarker platform, enhancing clinical trials with personalized, predictive criteria for safety and efficiency.","breadcrumb":{"@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/#primaryimage","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/11\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/11\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp","width":1456,"height":816,"caption":"image of an aptamer under a microscope"},{"@type":"BreadcrumbList","@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neoaptamers.com\/"},{"@type":"ListItem","position":2,"name":"Aptamarker Use Case: Enhancing Clinical Trials with Aptamarker Precision \u2013 Tailoring Inclusion and Exclusion Criteria"}]},{"@type":"WebSite","@id":"https:\/\/neoaptamers.com\/#website","url":"https:\/\/neoaptamers.com\/","name":"Neoaptamers.com","description":"Neoventures Biotechnology Inc.","publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/neoaptamers.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/neoaptamers.com\/#organization","name":"NeoVentures Biotechnology Inc.","alternateName":"NVB","url":"https:\/\/neoaptamers.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","width":500,"height":500,"caption":"NeoVentures Biotechnology Inc."},"image":{"@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/neoventures-biotechnology-inc-\/","https:\/\/www.reddit.com\/user\/NeoVenturesBiotech\/","https:\/\/www.youtube.com\/@neoaptamers7964"]},{"@type":"Person","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/641d6a3e016e13414b8d0d0ffd5847ad","name":"Gregory Penner","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","caption":"Gregory Penner"},"description":"Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. \u00a0He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team."}]}},"_links":{"self":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts\/5642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/comments?post=5642"}],"version-history":[{"count":1,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts\/5642\/revisions"}],"predecessor-version":[{"id":5643,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts\/5642\/revisions\/5643"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/media\/5644"}],"wp:attachment":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/media?parent=5642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/categories?post=5642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/tags?post=5642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}